Carugno et al. hypothesized an involvement of interleukin 17 in the genesis of erythematoedematous morbilliform rash in a patient previously suffering from psoriasis and treated with the monoclonal antibody secukinumab [45]. The gene discussed is IL17A; the disease is psoriasis.